| Literature DB >> 30909640 |
Marina Sartini1, Nicola Luigi Bragazzi2, Anna Maria Spagnolo3, Elisa Schinca4, Gianluca Ottria5, Chiara Dupont6, Maria Luisa Cristina7.
Abstract
Coffee is a blend of compounds related to gastrointestinal physiology. Given its popularity and the epidemiology of colorectal cancer, the impact of this beverage on public health could be considerable. Our aim was to provide an updated synthesis of the relationship between coffee consumption and the risk of colorectal cancer. We conducted a systematic review and meta-analysis of 26 prospective studies. Regarding colorectal cancer, no significant relationship was detected. Stratifying for ethnicity, a protective effect emerged in US subjects. Concerning colon cancer, coffee proved to exert a protective effect in men and women combined and in men alone. Stratifying for ethnicity, a significant protective effect was noted in European men only and in Asian women only. Concerning rectal cancer, no association was found. Decaffeinated coffee exhibited a protective effect against colorectal cancer in men and women combined. Studies were appraised for their quality by means of the Newcastle-Ottawa Quality Assessment Scale for Cohort studies. Only one study proved to be of low quality. Ethnicity could explain the heterogeneity of the studies. However, little is known about the relationship between the genetic make-up and the risk of colorectal cancer associated with coffee. Further research is warranted.Entities:
Keywords: cancer prevention; coffee/caffeine; colorectal cancer; epidemiology; prospective studies; systematic review and meta-analysis
Mesh:
Substances:
Year: 2019 PMID: 30909640 PMCID: PMC6471028 DOI: 10.3390/nu11030694
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Search strategy adopted in the present systematic review and meta-analysis.
| Search Strategy | Details |
|---|---|
| Search string | (coffee OR caffeine) AND (tumor OR cancer OR neoplasm) AND (colon OR rectal OR colorectal) |
| Databases | PubMed/MEDLINE, Scopus |
| Inclusion criteria | P (patients/population): general population/patients suffering from colorectal cancer |
| Exclusion criteria | Experimental studies investigating in vitro or animal models |
| Time filter | None (from inception) |
| Language filter | None (any language) |
Figure 1Flowchart of study selection, inclusion and synthesis.
Characteristics of studies included.
| First Authors (year) | Country | Study Subject | Coffee Consumption | No. Cases |
|---|---|---|---|---|
|
| Sweden | All (16,555) | ≥7 cups/d vs. ≤2 cups/d | 97 CC—63 RC |
|
| USA | All (11,632) | ≥4 cups/d vs. ≤1 cup/d | NA (CRC) |
|
| USA | All (10,572) | Continuous variable (cups/d) | 203 CC—66 RC |
|
| Sweden | F (21,238); | ≥7 cups/d vs. ≤2 cups/d | F: 52 CC—38 RC; |
|
| Sweden | F (61,463) | ≥4 cups/d vs. <1 cup/d | 291 CC—159 RC—460 CRC |
|
| Japan | F (1634); | Continuous variable (cups/d) | F: 14 CRC; M: 15 CRC |
|
| USA | All (133,893) | >5 cups/d vs. none (caffeinated, decaffeinated) | Caffeinated: 1170 CC—260 RC—1431 CRC |
|
| Sweden | All (106,739) | ≥4 cups/d vs. <1 cup/d | 843 CC—440 RC—1279 CRC |
|
| Sweden | F (61,467) | ≥4 cups/d vs. ≤1 cup/d | 504 CC—237 RC—741 CRC |
|
| Japan | F (16,327); | ≥1 cups/d vs. none | F: 102 CC; M: 111 CC |
|
| Japan | F (50,139); | ≥3 cups/d vs. none | F: 286 CC—151 RC—437 CRC |
|
| Japan | All (47,605) | ≥3 cups/d vs. none | ALL: 281 CC—180 RC—457 CRC |
|
| Finland | All (60,041) | ≥10 cups/d vs. none | ALL: 333 CC—252 RC—538 CRC |
|
| Sweden | All (64,603) | ≥4 cups/d vs. <1 cup/d | 321 CRC |
|
| Netherlands | F (62,573) | >6 cups/d vs. ≤2 cups/d | F: 173 RC—939 CRC |
|
| Multi-center (conducted in USA and in Europe) | All (731,441) | High quintile vs. low quintile | 5,604 CC |
|
| USA | All (489,706) | ≥6 cups/d vs. none | 5,072 CC—2863 Prox CC—1993 Distal CC—1874 RC—6946 CRC |
|
| USA | All (57,398) | ≥4 cups/d vs. none | 681 CRC |
|
| USA | All (67,912) | ≥7 cups/d vs. <7 cups/d | 409 CRC |
|
| EPIC study | All (521,448) | High quintile vs. low quintile | 2691 CC—1242 Prox CC—1202 Distal CC—1543 RC—4234 CRC |
|
| Finland | M (27,111) | >6 cups/d vs. ≤4 cups/d | 106 CC—79 RC |
|
| Singapore | All (61,321) | ≥2 cups/d vs. <1 cup/d | 591 CC—370 RC |
|
| Japan | F (34,614) | ≥4 cups/d vs. <1 cup/d | F: 332 CC—112 RC—444 CRC |
|
| USA | F (83,972) | ≥4 cups/d vs. none | 1,083 CC—160 RC—12,852 CRC |
|
| Norway | F (79,461) | >7 cups/d vs. ≤1 cup/d | 1266 CRC |
|
| Japan | F (170,388) | ≥3 cups/d vs. <1 cup/d | F: 1963 CC—770 RC—2689 CRC |
Abbreviations: CC (colon cancer); CRC (colorectal cancer); d (day); F (female); M (male); NA (not available); prox (proximal); RC (rectal cancer); vs. (versus).
Risk ratio (RR) and 95% CI for all meta-analyses carried out. Values in bold are statistically significant.
|
| Men and Women | Men | Women | |
|---|---|---|---|---|
| RR [95%CI]; | RR [95%CI]; | RR [95%CI]; | ||
|
| All | 0.96 [0.88–1.03]: (8) | 0.96 [0.88–1.04]; (9) | 1.06 [0.97–1.14]; (13) |
| EU studies only | 1.07 [0.96–1.17]; (4) | 0.93 [0.80–1.06]; (3) | 1.10 [0.98–1.22]; (6) | |
| Asian studies only | NA | 0.97 [0.87–1.08]; (5) | 0.94 [0.78–1.09]; (5) | |
| USA studies only |
| NA | 1.14 [0.92–1.36]; (2) | |
| Caffeinated coffee | 0.96 [0.77–1.17]; (3) | NA | NA | |
| Decaffeinated coffee |
| NA | NA | |
|
| All |
|
| 0.92 [0.80–1.03]; (13) |
| EU studies only | 0.96 [0.84–1.09]; (4) |
| 1.05 [0.93–1.18]; (5) | |
| Asian studies only | 0.91 [0.73–1.09]; (2) | 0.94 [0.82–1.06]; (5) |
| |
| USA studies only | 0.83 [0.66–1.01]; (2) | NA | 0.90 [0.38–1.42]; (2) | |
| Caffeinated coffee | 0.92 [0.68–1.15]; (3) | NA | NA | |
| Decaffeinated coffee | 0.93 [0.81–1.05]; (3) | NA | NA | |
|
| All | 0.98 [0.95–1.02]; (5) | 0.94 [0.87–1.01]; (5) | 1.00 [0.96–1.04]; (6) |
| EU studies only | NA |
| 1.09 [0.82–1.36]; (3) | |
| Asian studies only | NA | 0.83 [0.60–1.05]; (2) | 0.91 [0.56–1.25]; (2) | |
| USA studies only | 0.88 [0.65–1.12]; (2) | NA | NA | |
| Caffeinated coffee | 0.99 [0.79–1.91]; (2) | NA | NA | |
| Decaffeinated coffee | 1.05 [0.79–1.32]; (2) | NA | NA | |
|
| All | 0.93 [0.73–1.15]; (5) | 0.98 [0.92–1.04]; (5) | 0.99 [0.96–1.03]; (6) |
| EU studies only | NA | 0.90 [0.66–1.14]; (2) | 1.17 [0.90–1.44]; (3) | |
| Asian studies only | NA | 1.08 [0.83–1.32]; (2) | 0.85 [0.57–1.13]; (2) | |
| USA studies only | 0.92 [0.23–1.60]; (2) | NA | NA | |
| Caffeinated coffee | 0.85 [0.32–1.36]; (2) | NA | NA | |
| Decaffeinated coffee | 0.86 [0.66–1.06]; (2) | NA | NA | |
|
| All | 1.00 [0.89–1.11]; (9) | 1.01 [0.87–1.14]; (9) | 1.08 [0.94–1.23]; (11) |
| EU studies only | 1.17 [0.97–1.37]; (4) | 0.96 [0.78–1.14]; (5) | 1.04 [0.87–1.21]; (6) | |
| Asian studies only | 1.04 [0.79–1.29]; (2) | 1.07 [0.85–1.29]; (4) | 1.28 [0.96–1.60]; (4) | |
| USA studies only | 0.88 [0.72–1.04]; (3) | NA | NA | |
| Caffeinated coffee | 1.18 [0.98–1.38]; (3) | NA | NA | |
| Decaffeinated coffee | 0.71 [0.41–1.01]; (3) | NA | NA | |
Abbreviations: CC (colon cancer); CRC (colorectal cancer); EU (European countries); NA (not available); RC (rectal cancer).
Figure 2Forest plot of colon cancer in men and women combined.
Figure 3Forest plot of colon cancer in men.
Figure 4Forest plot of colon cancer in European men (A) and in Asian women (B).